GM1 gangliosidosis, caused by biallelic variants in GLB1, results from deficiency of lysosomal β-galactosidase, which degrades GM1 ganglioside. This fatal neurodegenerative disease currently has no ...
First-in-human DS3790 trial tests a CD37-targeted ADC for relapsed/refractory B-cell non-Hodgkin lymphoma, aiming to improve response durability and survival. In a milestone for the hematologic ...
NEO-811 is a novel molecular glue degrader intended to fully block a key clear cell renal cell carcinoma signaling pathway via cereblon-dependent target degradation. The primary outcome measures for ...
Hosted on MSN
Tricky mod phase 3 is literal madness! [Part 1]
Homeowners don’t want to move. It’s a big deal for their shrinking backyards. South Korean former president sentenced to 5 years in prison over martial law Why the Trump administration is obsessed ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) today announced that the first patients have been dosed in the Phase 2 portion of its ...
EMERYVILLE, Calif., Dec. 24, 2025 /PRNewswire/ -- Sanofi announced today that it has entered into an agreement to acquire Dynavax Technologies Corporation (Nasdaq: DVAX), a publicly traded vaccines ...
(RTTNews) - Monte Rosa Therapeutics, Inc. (GLUE) today will present updated interim results from its ongoing Phase 1/2 study of MRT-2359 in patients with metastatic castration-resistant prostate ...
CAMBRIDGE, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (BEAM) (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...
Hosted on MSN
Skeleton Tricky and Steve FNF Mod
VaporTheGamer reacts to skeleton tricky phase 5 and minecraft steve in friday night funkin'! (friday night mining/tricky 5) with fun commentary, unique insights, and FNAF or FNF fan excitement. Alina ...
Intensity Therapeutics (INTS), with a ~$13M market cap, closed up nearly 395% Thursday after publishing phase 1/2 results on its candidate for metastatic or refractory cancers, INT230-6. The asset ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The allogenic cell therapy achieved all primary and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results